51
|
Gauthier S, Johnson K, Dubois B. Communicating the diagnosis of Alzheimer's disease: Dilemmas and perspectives. Neurobiol Aging 2014. [DOI: 10.1016/j.neurobiolaging.2014.01.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
52
|
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE 2014; 1:110-116. [PMID: 29255837 DOI: 10.14283/jpad.2014.6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Successful therapeutic trials require well-targeted populations to demonstrate the effectiveness of a drug candidate. Most trials in the field of Alzheimer's disease (AD) have been conducted in patients with mild to moderate dementia. However, the advent of amyloid PET imaging has demonstrated that a significant proportion of individuals enrolled in such studies do not have evidence of brain amyloidosis and may in fact not have Alzheimer's disease. Further, dementia represents an advanced stage of neurodegeneration, perhaps too late for significant benefits of disease-modifying interventions. The successful development of effective disease-slowing therapies requires a study population selected in accordance with the mechanism of the specific intervention. An international task force of investigators from academia, industry, non-profit foundations, and regulatory agencies met in San Diego, California, USA, on November 13, 2013, to address issues related to screening and identification of clinical trial participants, and the ramifications of decisions made in this regard for drug development in AD and other dementias.
Collapse
|
53
|
Azuar C, Reyes P, Slachevsky A, Volle E, Kinkingnehun S, Kouneiher F, Bravo E, Dubois B, Koechlin E, Levy R. Testing the model of caudo-rostral organization of cognitive control in the human with frontal lesions. Neuroimage 2014; 84:1053-60. [DOI: 10.1016/j.neuroimage.2013.09.031] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2013] [Revised: 09/05/2013] [Accepted: 09/13/2013] [Indexed: 11/25/2022] Open
|
54
|
Agüero MGD, Macari C, Vocanson M, Salou M, Pingris K, Kaiserlian D, Dubois B. Cellules de Langerhans et contrôle de la réactivité cutanée aux allergènes de contact. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
55
|
Mokri H, Matharan F, Pérès K, Bouisson J, Dartigues JF, Amieva H, Dubois B. Le test des gobelets : normes et propriétés de détection d’un trouble cognitif chez des sujets sélectionnés en population générale. Rev Neurol (Paris) 2013; 169:871-8. [DOI: 10.1016/j.neurol.2013.01.626] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 12/04/2012] [Accepted: 01/21/2013] [Indexed: 11/29/2022]
|
56
|
Teichmann M, Kas A, Boutet C, Ferrieux S, Nogues M, Samri D, Rogan C, Dormont D, Dubois B, Migliaccio R. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain 2013; 136:3474-88. [DOI: 10.1093/brain/awt266] [Citation(s) in RCA: 124] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
57
|
Hannequin D, Amieva H, Dubois B, Godefroy O, Pasquier F. [Dementia: new concepts, new goals]. Rev Neurol (Paris) 2013; 169:677-9. [PMID: 24074818 DOI: 10.1016/j.neurol.2013.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2013] [Accepted: 09/11/2013] [Indexed: 10/26/2022]
|
58
|
Defontaines B, Uspenskaya O, Paquet C, Gnassounou R, Denolle S, Hugon J, Dubois B. Le réseau Aloïs et les CM2R en Île de France : un partenariat innovant pour l’inclusion des patients de ville dans les protocoles de recherche. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
59
|
Robert PH, Konig A, Andrieu S, Bremond F, Chemin I, Chung PC, Dartigues JF, Dubois B, Feutren G, Guillemaud R, Kenisberg PA, Nave S, Vellas B, Verhey F, Yesavage J, Mallea P. Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting. J Nutr Health Aging 2013; 17:653-60. [PMID: 24097018 DOI: 10.1007/s12603-013-0046-3] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Alzheimer disease (AD) and other related dementia represent a major challenge for health care systems within the aging population. It is therefore important to develop better instruments for assessing disease severity and disease progression to optimize patient's care and support to care providers, and also provide better tools for clinical research. In this area, Information and Communication Technologies (ICT) are of particular interest. Such techniques enable accurate and standardized assessments of patients' performance and actions in real time and real life situations. The aim of this article is to provide basic recommendation concerning the development and the use of ICT for Alzheimer's disease and related disorders. During he ICT and Mental Health workshop (CTAD meeting held in Monaco on the 30th October 2012) an expert panel was set up to prepare the first recommendations for the use of ICT in dementia research. The expert panel included geriatrician, epidemiologist, neurologist, psychiatrist, psychologist, ICT engineers, representatives from the industry and patient association. The recommendations are divided into three sections corresponding to 1/ the clinical targets of interest for the use of ICT, 2/ the conditions, the type of sensors and the outputs (scores) that could be used and obtained, 3/ finally the last section concerns specifically the use of ICT within clinical trials.
Collapse
|
60
|
Poinso F, Dubois B, Chatel C, Viellard M, Bastard-Rosset D, Girardot AM, Grandgeorge P, De Martino S, Sokolowsky M, Salle-Collemiche X, Da Fonseca D. [Prospective assessment of children with pervasive developmental disorder after 2 years of day-hospital treatment]. Arch Pediatr 2012; 20:17-25. [PMID: 23219270 DOI: 10.1016/j.arcped.2012.10.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 09/22/2012] [Accepted: 10/26/2012] [Indexed: 11/16/2022]
Abstract
The treatment of children with pervasive developmental disorders (PDD) has not been systematically assessed in French day-care units. In this prospective study, 11 children with a diagnosis of PDD were followed up for 2years in a day-care unit in the Marseille university hospital. The treatment they received is based on an initial assessment by the "Centre Ressources Autisme" (CRA PACA) and further included a continued observation of the child and an assessment of the child's abilities and needs. This treatment used various therapeutic approaches 10h weekly and also included parental counseling and coordinated work with schools. Treatment in our day-care unit can be categorized as eclectic, non-intensive therapy. It is based on methods such as TEACCH (Treatment and Education of Autistic and related Communication handicapped Children), Floor Time Play, speech and language therapy, developmental therapy, and psychotherapy. International studies on intensive behavioral therapies suggest that this treatment is superior to non-behavioral and/or non-intensive treatment. They suggest its efficiency is due both to the nature of the treatment (behavioral) and to its intensity (more than 25h a week). In this study, the CRA diagnosed children using the ADI and ADOS. The 11 children (mean age, 3years 5months) were tested twice, with the Vineland and CARS scales. The first assessment was on admission to the day hospital and the second was 2years later. The results showed developmental progress with a mean increase of 13.5 months at the Vineland Scale, and a decrease of the autism severity score on the CARS. The treatment presented here proves to be efficient; if compared to similar results in international studies, we obtained better results than their eclectic intensive or non-intensive treatment comparison group.
Collapse
|
61
|
de Souza LC, Sarazin M, Uspenskaya O, Habert MO, Lamari F, Lehéricy S, Dubois B. [Markers of prodromal Alzheimer's disease]. Rev Neurol (Paris) 2012; 168:815-24. [PMID: 22944619 DOI: 10.1016/j.neurol.2012.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The diagnosis of Alzheimer's disease has long been considered a diagnosis of probability, as the definitive diagnosis can only be established by histopathological examination. However, the development of in-vivo biomarkers, considered a reflection of physiopathological processes, has changed our view of the disease. New criteria have recently been proposed that integrate such biomarkers as found in the cerebrospinal fluid (CSF) using new diagnostic tools such as magnetic resonance imaging (MRI), brain scintigraphy, FDG-positron emission tomography (PET) and PET amyloid ligand uptake studies. The value of these new criteria for the diagnosis of prodromal Alzheimer's disease and the prospect of disease-modifying drugs are also discussed.
Collapse
|
62
|
Delanaye P, Claisse G, Mehdi M, Maillard N, Lambermont B, Dubois B, Damas P, Krzesinski JM, Morel J, Lautrette A, Cavalier E, Mariat C. Le débit de filtration glomérulaire est-il un déterminant de la concentration plasmatique du NGAL aux soins intensifs ? Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Delanaye P, Cavalier E, Mehdi M, Maillard N, Lambermont B, Dubois B, Damas P, Krzesinski JM, Morel J, Lautrette A, Mariat C. Intérêt de la cystatine C aux soins intensifs : validation par rapport à une mesure de référence du débit de filtration glomérulaire. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
64
|
Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, Jack CR, Johannsen P, Miller BL, Nestor PJ, Scheltens P, Sorbi S, Teipel S, Thompson PM, Wahlund LO. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012; 19:e131-40, 1487-501. [DOI: 10.1111/j.1468-1331.2012.03859.x] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Accepted: 07/18/2012] [Indexed: 01/18/2023]
|
65
|
Dubois B. [For a new definition of the Alzheimer's disease]. Rev Neurol (Paris) 2012; 168:467-8. [PMID: 22560011 DOI: 10.1016/j.neurol.2012.03.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Revised: 10/24/2010] [Accepted: 03/21/2012] [Indexed: 11/26/2022]
|
66
|
Le Ber I, Camuzat A, Guillot-Noel L, Guedj E, Hannequin D, Wargon I, Couratier P, Deramecourt V, Berger E, Viennet G, Pasquier F, Lacomblez Aurousseau L, Salachas F, Martinaud O, Golfier V, Puel M, Vercelletto M, Didic M, Sauvee M, Sellal F, Thomas-Anterion C, Campion D, Michel B, Dubois B, Camu W, Seilhean D, Meininger V, Habert MO, Duyckaerts C, Brice A. Frequency and Phenotypes Associated with C9ORF72 Repeat Expansion in French FTLD and FTLD-ALS Patients (S54.003). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s54.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
67
|
Migliaccio R, Roue-Jagot C, Dubois B, Teichmann M. Logopenic Variant of Primary Progressive Aphasia in Lewy Body Dementia: Beyond Alzheimer's Disease (P05.038). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
68
|
Barton B, Bernard B, Stebbins G, Goldman J, Dubois B, Goetz C. Comparison of Movement Disorder Society Criteria for Parkinson's Disease Dementia with Routine Clinical Neuropsychological Testing (PD4.006). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.pd4.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
69
|
Migliaccio R, Gallea C, Andrade K, Samri D, Lehericy S, Dubois B, Bartolomeo P. Resting State Functional Connectivity in Posterior Cortical Atrophy (P03.086). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p03.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
70
|
de Souza L, Corlier F, Habert MO, Lamari F, Hahn-Barma V, Maroy R, Dubois B, Bottlaender M, Sarazin M. Application of the New Research Criteria for AD and Validation of a Hippocampal Memory Test Using PET-Amyloid Imaging (PD1.007). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.pd1.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
71
|
Funkiewiez-Guignebert A, Bertoux ML, Cruz De Souza L, Dubois B. Démence fronto-temporale et processus socio-affectifs. Rev Neurol (Paris) 2012. [DOI: 10.1016/j.neurol.2012.01.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
72
|
Le Ber I, Camuzat A, Hannequin D, Lacomblez L, Couratier P, Guillot-Noel L, Habert M, Seilhean D, Golfier V, Puel M, Martinaud O, Deramecourt V, Vercelletto M, Sellal F, Pasquier F, Salachas F, Thomas-Anterion C, Didic M, Pariente J, Wargon I, Blanc F, Michel B, Berger E, Sauvee M, Mondon K, Fleury M, Meininger V, Duyckaerts C, Dubois B, Guedj E, Brice A. Fréquence et phénotypes associés aux mutations du gène c9orf72 dans une cohorte française de patients atteints de DLFT. Rev Neurol (Paris) 2012. [DOI: 10.1016/j.neurol.2012.01.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
73
|
Cagliani R, Guerini FR, Fumagalli M, Riva S, Agliardi C, Galimberti D, Pozzoli U, Goris A, Dubois B, Fenoglio C, Forni D, Sanna S, Zara I, Pitzalis M, Zoledziewska M, Cucca F, Marini F, Comi GP, Scarpini E, Bresolin N, Clerici M, Sironi M. A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. Mol Biol Evol 2012; 29:1599-613. [PMID: 22319148 PMCID: PMC7187542 DOI: 10.1093/molbev/mss002] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
The human ZC3HAV1 gene encodes an antiviral protein. The longest splicing isoform of ZC3HAV1 contains a C-terminal PARP-like domain, which has evolved under positive selection in primates. We analyzed the evolutionary history of this same domain in humans and in Pan troglodytes. We identified two variants that segregate in both humans and chimpanzees; one of them (rs3735007) does not occur at a hypermutable site and accounts for a nonsynonymous substitution (Thr851Ile). The probability that the two trans-specific polymorphisms have occurred independently in the two lineages was estimated to be low (P = 0.0054), suggesting that at least one of them has arisen before speciation and has been maintained by selection. Population genetic analyses in humans indicated that the region surrounding the shared variants displays strong evidences of long-standing balancing selection. Selection signatures were also observed in a chimpanzee population sample. Inspection of 1000 Genomes data confirmed these findings but indicated that search for selection signatures using low-coverage whole-genome data may need masking of repetitive sequences. A case–control study of more than 1,000 individuals from mainland Italy indicated that the Thr851Ile SNP is significantly associated with susceptibility to multiple sclerosis (MS) (odds ratio [OR] = 1.47, 95% confidence intervals [CI]: 1.08–1.99, P = 0.011). This finding was confirmed in a larger sample of 4,416 Sardinians cases/controls (OR = 1.18, 95% CI: 1.037–1.344, P = 0.011), but not in a population from Belgium. We provide one of the first instances of human/chimpanzee trans-specific coding variant located outside the major histocompatibility complex region. The selective pressure is likely to be virus driven; in modern populations, this variant associates with susceptibility to MS, possibly via the interaction with environmental factors.
Collapse
|
74
|
Bloch F, Bonnet AM, Chamayou C, Hergueta T, Pointon C, Mourlon V, Leber I, Dubois B. 1.206 UPDATE IN THE CLINICAL PRESENTATION AND NATURAL HISTORY OF DCB AND PSP PATIENTS. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70264-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
75
|
Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, Fiévet N, Brouwers N, Bettens K, Arosio B, Coto E, Del Zompo M, Mateo I, Epelbaum J, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Soininen H, Dartigues JF, Kamboh MI, Van Broeckhoven C, Lambert JC, Amouyel P, Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16:903-7. [PMID: 21556001 PMCID: PMC3162068 DOI: 10.1038/mp.2011.52] [Citation(s) in RCA: 467] [Impact Index Per Article: 35.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2011] [Accepted: 04/01/2011] [Indexed: 12/16/2022]
Abstract
Apolipoprotein E (APOE) dependent lifetime risks (LTRs) for Alzheimer Disease (AD) are currently not accurately known and odds ratios alone are insufficient to assess these risks. We calculated AD LTR in 7351 cases and 10 132 controls from Caucasian ancestry using Rochester (USA) incidence data. At the age of 85 the LTR of AD without reference to APOE genotype was 11% in males and 14% in females. At the same age, this risk ranged from 51% for APOE44 male carriers to 60% for APOE44 female carriers, and from 23% for APOE34 male carriers to 30% for APOE34 female carriers, consistent with semi-dominant inheritance of a moderately penetrant gene. Using PAQUID (France) incidence data, estimates were globally similar except that at age 85 the LTRs reached 68 and 35% for APOE 44 and APOE 34 female carriers, respectively. These risks are more similar to those of major genes in Mendelian diseases, such as BRCA1 in breast cancer, than those of low-risk common alleles identified by recent GWAS in complex diseases. In addition, stratification of our data by age groups clearly demonstrates that APOE4 is a risk factor not only for late-onset but for early-onset AD as well. Together, these results urge a reappraisal of the impact of APOE in Alzheimer disease.
Collapse
|